Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
VBC-103 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
VBC-103: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LCB-84 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
LCB-84: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Elticertinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Elticertinib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TELOMIR-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
TELOMIR-1: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vecabrutinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Vecabrutinib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Mocaciclib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Mocaciclib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vustanaciclib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Vustanaciclib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
4D-710 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
4D-710: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HYD-PEP06 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
HYD-PEP06: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review.
8 min read
BGP-15 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
BGP-15: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
JKN2403 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
JKN2403: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.